TFF Pharmaceuticals said that it has received a notice of allowance for US Patent Application No. 12/778,795, titled, "Compositions and Methods of Making Brittle-Matrix Particles Through Blister Pack Freezing," which covers technology related to the company's DPI products for respiratory conditions. Earlier this year, TFF announced that it had raised $14 million … [Read more...] about TFF Pharmaceuticals announces US patent for DPI particle technology
Business
Seqirus gets rights to market Ryaltris nasal spray in Australia and New Zealand
Glenmark Pharmaceuticals has announced that it will receive an unspecified amount up front, plus regulatory and commercial milestone payments, from Seqirus for the rights to commercialize Ryaltris olopatadine hydrochloride/mometasone furoate nasal spray in Australia and New Zealand. In December 2017, Glenmark announced positive results from a Phase 3 trial of … [Read more...] about Seqirus gets rights to market Ryaltris nasal spray in Australia and New Zealand
Senzer announces plans to launch cannabidiol inhalation solution in UK
Senzer Ltd has announced plans to launch several inhaled cannabinoid products in the UK, beginning with its Cannafen cannabidiol inhalation solution later this year. Senzer is a subsidiary of Kind Consumer, whose Voke nicotine inhaler was approved by the MHRA for nicotine cessation in 2014. The company will launch the inhaled cannabinoid product under a specials … [Read more...] about Senzer announces plans to launch cannabidiol inhalation solution in UK
Menarini to market Orion DPIs in Asia-Pacific region
Menarini Asia-Pacific Holdings has signed a multi-year licensing agreement with Orion Corporation for distribution and commercialization of Easyhaler DPI products in China, Hong Kong, Philippines, Malaysia, Indonesia, Thailand, Singapore, Vietnam, Taiwan, and South Korea, the companies said. In 2016, Menarini and Orion announced that Menarini would co-market … [Read more...] about Menarini to market Orion DPIs in Asia-Pacific region
US appeals court affirms ruling on validity of Zomig nasal spray patents
Amneal Pharmaceuticals announced that the US Court of Appeals for the Federal Circuit has upheld a March 2017 ruling finding that Lannett infringed on US patents 6,750,237 and 7,220,767, which are related to Zomig zolmitriptan nasal spray. Impax Laboratories, an Amneal subsidiary, and AstraZeneca filed suit against Lannett after Lannett filed an ANDA for a generic … [Read more...] about US appeals court affirms ruling on validity of Zomig nasal spray patents
Lupin launches generic tobramycin inhalation solution in US
Lupin has launched its generic version of Tobi inhalation solution in the US, the company said. The FDA granted final approval of Lupin's ANDA for its tobramycin inhalation inhalation solution in March 2017. The 300 mg/5 ml inhalation solution is indicated for the treatment of P. aeruginosa lung infections in cystic fibrosis patients. Read the Lupin press … [Read more...] about Lupin launches generic tobramycin inhalation solution in US
Pivot Pharmaceuticals signs option agreement for Trivair device for delivery of dry powder cannabinoid formulations
Pivot Pharmaceuticals has announced that the company signed an option agreement with IP Med Inc. for an exclusive worldwide license for use of TriVair nasal and pulmonary breath-propelled devices for delivery of dry powder cannabinoid formulations. Pivot will have 6 months to evaluate the use of the device for delivery of its Ready-To-Infuse-Cannabis ("RTIC") to … [Read more...] about Pivot Pharmaceuticals signs option agreement for Trivair device for delivery of dry powder cannabinoid formulations
Apotex recalls lot of fluticasone nasal spray in US
Apotex has issued a voluntarily recall for one lot of fluticasone propionate nasal spray (lot NJ4501), which was shipped to wholesalers and distributors throughout the US and has an expiration date of July 2020. Apotex said that the FDA is aware of the recall and wholesalers and distributors have been notified. According to the company, a consumer complaint … [Read more...] about Apotex recalls lot of fluticasone nasal spray in US
Dry powder nitric oxide release formulation reduces bacterial load of NTM by 99% in preclinical study
Vast Therapeutics, which recently changed its name from Novoclem Therapeutics, has announced that its BIOC51 dry powder nitric oxide (NO)-release formulation reduced the bacterial load of nontuberculous mycobacteria (NTM) in the lungs of mice by 99% in a study conducted with Colorado State University. According to the company, BIOC51 has eradicated every bacterial … [Read more...] about Dry powder nitric oxide release formulation reduces bacterial load of NTM by 99% in preclinical study
Windtree Therapeutics gets $700,000 for follow-up to Phase 2b Aerosurf study
Windtree Therapeutics has received the remaining $700,000 from a Small Business Innovation Research Grant (SBIR) from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) that was initially awarded in 2016 for Phase 2 development of Aerosurf. The company previously received a total of $1.9 million from that award, an … [Read more...] about Windtree Therapeutics gets $700,000 for follow-up to Phase 2b Aerosurf study